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levels  1.0 (7.2  7.7 days vs. 5.5  5.6 days) after risk adjust-
ment the actual to predicted LOS ratio was not signiﬁcantly
different from 1. CONCLUSION: The majority of cases have
serum digoxin levels that are above the currently recommended
range and cases with serum digoxin levels  1.0 have a higher
mortality. Cases with serum digoxin levels  1.0 did not have
higher risk-adjusted LOS. Digoxin dosing during hospitalization
requires careful monitoring and has the potential of improving
safety and related outcomes.
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OBJECTIVE: The various off-label uses of intravenous immune
globulin (IVIG), used for the treatment of immunodeﬁciency
disorders, far exceeds its labeled indications. This study repre-
sents an effort to identify these uses. METHODS: Clinical studies
concerning the off-label uses of IVIG preparations were identiﬁed
by searching the PUBMED (MEDLINE+) database from January
1, 1998 to January 1, 2006. The search was limited to clinical
trials, meta-analyses, randomized controlled trials, and case
reports in English. RESULTS: A review of 138 clinical trial
abstracts identiﬁed 10 trials examining 2 labeled uses (635
patients) and 128 trials examining 61 different off-label uses
(6781 patients). The top off-label indications included multiple
sclerosis, graft versus host disease in transplant patients, preven-
tion of antiphospholipid syndrome in miscarriage, and Guillan-
Barre syndrome. The studies appear to support many of the
acceptable off-label uses cited by various guideline groups. A
total of 276 case reports were identiﬁed, with 268 reports rep-
resenting 156 different off-label uses (362 patients). Patient out-
comes from published abstracts were positive for 267 patients
(74%). Seven meta-analyses were identiﬁed, evaluating recurrent
miscarriage, in vitro fertilization failure, infection in preterm
infants, multiple sclerosis, immune thrombocytopenic purpura,
and pemphigoid. With the exception of recurrent miscarriage and
infection in preterm infants, the off-label use of IVIG for these
indications was found to have positive outcomes. CONCLU-
SION: Over 150 off-label uses were identiﬁed from reviewing
clinical trials and case reports. An examination of IVIG guide-
lines by specialty society, payer, and other review organizations
shows that the biomedical evidence supporting off-label uses is
being interpreted in different ways. Health care institutions are
strongly urged to approve and closely monitor speciﬁc uses of
IVIG to reserve dwindling supplies for the “best evidence” uses.
Clinicians should be aware of the limits of knowledge in many
off-label uses and exercise restraint in prescribing for unproven
indications.
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OBJECTIVE: Current national patient safety goals call to
“Reduce the likelihood of patient harm associated with the use
of anticoagulation therapy”. We examined the epidemiology,
length of stay and occurrence of bleeding in non-surgical
patients treated with heparin infusions during hospitalization.
METHODS: We retrospectively analyzed 668 non-surgical cases
that were treated with heparin for at least 24 hours during
hospitalization from 2 institutions that electronically provided
laboratory and pharmacy data from 2005–2006. Cases were
categorized into the following groups based on serum APTT
results; subtherapeutic (<51), therapeutic (51–75), above thera-
peutic (76–99) and supratherapeutic (100). The number of
cases meeting each APPT category was compared at approxi-
mately 6 and 24 hours post heparin treatment. The actual to
predicted hospital length of stay was compared for each APTT
category with predicted LOS determined using previously
described admission based clinical models. Bleeding was assessed
by the presence of diagnostic codes. RESULTS: Those with
APTT measured, the percent of cases at 6 and 24 hours were;
20.7 vs. 20.3 for subtherapeutic, 23.4 vs. 31.6 for therapeutic,
16.2 vs. 19.0 for above therapeutic, and 30.4 vs. 18.6 for supra-
therapeutic. There was a 1.8 day excess LOS in the subthera-
peutic group at 24 hours (p < 0.05). Unadjusted bleeding rates
were 21.6% for subtherapeutic, 17.5% in therapeutic, 13.4% in
above therapeutic and 12.1% in supratherapeutic cases at 24
hours. CONCLUSION: One in 5 cases treated with heparin had
a subtherapeutic APTT at 24 hours and these cases had a sig-
niﬁcantly longer LOS. Clinicians responsible for assuring anti-
coagulation safety should incorporate monitoring strategies for
subtherapeutic APTT results as diligently as those for suprath-
erapeutic results.
HEALTH CARE USE & POLICY STUDIES—
Equity and Access
PHP40
ANALYZING INEQUITY IN HEALTH CARE UTILIZATION BY
THE US POPULATION
Kawatkar AA, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To evaluate equity concerns in routine and pre-
ventive health care utilization. METHODS: Data from the
MEPS’s Household Component (2004), a nationally representa-
tive survey of the U.S. civilian noninstitutionalized population,
was used. Equity was deﬁned on the principle of equal treatment
for equal need. Need variables controlled in the model were
perceived health status, presence of illness, comorbidities, activi-
ties and instrumental activities of daily living limitations. Non-
need variables assessed for presence of horizontal equity were
age, gender, race, ethnicity, income, and education. Need vari-
ables were studied to conﬁrm presence of vertical equity, which
was deﬁned as different levels of need variables consuming
appropriate different levels of health care. Equity in routine
health care utilization namely-expenditures on Emergency room
(ER), Inpatient hospitalization (IPH), Outpatient care (OPT),
Ofﬁce-based care (OFB), Dental care (DENTAL), and Prescrip-
tion drugs (RX) were analyzed by GLM with log-link and
Gamma/Poisson families. Binary measures of dental check-up,
cholesterol check-up, blood-pressure check-up, and ﬂu-shots, as
indicators of preventive health care utilization, were analyzed by
logistic and skewed-logistic models. RESULTS: Horizontal ineq-
uity was observed by age, gender, and income in all routine care
variables except ER. Inequity by education was observed in OFB,
DENTAL, and RX. Race related inequity was observed in OFB,
IPH, DENTAL, and RX. Inequity by ethnicity was observed in
utilization of all routine care variables. Necessary condition for
vertical equity was not satisﬁed only in ER and DENTAL utili-
zation. Horizontal inequity was observed in all four preventive
care variables by age, gender, ethnicity, income, and education.
Horizontal inequity by race was observed in cholesterol check-
up, blood pressure check-up, and receipt of ﬂu shots. Evidence of
vertical equity was not observed in preventive care utilization.
CONCLUSION: Horizontal inequity in age, gender, race, ethnic-
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